Oncology News and Research

RSS
UKONS publishes position statement on safe, effective use of oral anticancer medicines

UKONS publishes position statement on safe, effective use of oral anticancer medicines

Role of surgery and subsequent need for RT in treatment of stage I SCLC

Role of surgery and subsequent need for RT in treatment of stage I SCLC

Researchers discover new strategy to overcome drug resistance in breast cancer

Researchers discover new strategy to overcome drug resistance in breast cancer

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

FDA approves risk management program on ESA's for treating anemia due to chemotherapy

FDA approves risk management program on ESA's for treating anemia due to chemotherapy

AZ&Me Prescription Savings programs help 13% more patients in 2009

AZ&Me Prescription Savings programs help 13% more patients in 2009

Research assesses the overall efficacy of palliative chest RT in patients with advanced NSCLC

Research assesses the overall efficacy of palliative chest RT in patients with advanced NSCLC

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

Quintiles' anatomic pathology services now available in China to help develop effective cancer treatments

Quintiles' anatomic pathology services now available in China to help develop effective cancer treatments

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

Merck announces global sales of $27.4 billion for full-year 2009

Merck announces global sales of $27.4 billion for full-year 2009

FDA’s radiation exposure-reduction initiative: HealthHelp’s model provides quality and safety

FDA’s radiation exposure-reduction initiative: HealthHelp’s model provides quality and safety

AstraZeneca, Rigel Pharmaceuticals announce exclusive worldwide license agreement for R788

AstraZeneca, Rigel Pharmaceuticals announce exclusive worldwide license agreement for R788

US Oncology honored as inaugural inductee to Texas Governor's Business Hall of Fame

US Oncology honored as inaugural inductee to Texas Governor's Business Hall of Fame

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

LCA announces new internet link with renowned lung cancer research center in Zhuhai, China

LCA announces new internet link with renowned lung cancer research center in Zhuhai, China

CEO Roundtable on Cancer salutes Duke Blue Devils basketball team coach on 1000th game

CEO Roundtable on Cancer salutes Duke Blue Devils basketball team coach on 1000th game

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.